Interventional Cardiology, Clinica Mediterranea, Via Orazio, 2, I-80121, Naples, Italy.
Circulation. 2010 May 18;121(19):2117-22. doi: 10.1161/CIRCULATIONAHA.109.919639. Epub 2010 May 3.
Cystatin C (CyC) is more sensitive than serum creatinine (sCr) to rapidly detect acute changes in renal function.
We measured CyC together with sCr in 410 consecutive patients with chronic kidney disease undergoing either coronary and/or peripheral angiography and/or angioplasty. sCr was assessed at baseline and 24 and 48 hours after contrast media exposure. CyC was assessed at baseline and at 24 hours. Major adverse events (including death of any cause and dialysis) at 12 months were assessed. At 48 hours after contrast media exposure, contrast-induced acute kidney injury (defined as a sCr increase > or =0.3 mg/dL) occurred in 34 patients (8.2%). A CyC increase concentration > or =10% at 24 hours after contrast media exposure was detected in 87 patients (21.2%). This was the best CyC cutoff for the early identification of patients at risk for contrast-induced acute kidney injury (negative predictive value=100%; positive predictive value=39.1%). According to the defined cutoffs (that is, increase in CyC > or =10% and sCr > or =0.3 mg/dL), major adverse events occurred in 16 of 297 patients (5.4%) without any cutoffs satisfied (group 1), in 9 of 49 patients (18.4%) with only a CyC increase > or =10% (group 2), and in 9 of 31 patients (29%) with both cutoffs satisfied (group 3). By logistic regression analysis, the independent predictors of major adverse events at 1 year were group 2 (odds ratio=2.52; 95% confidence interval, 1.17 to 5.41; P=0.02), group 3 (odds ratio=4.45; 95% confidence interval, 1.72 to 11.54; P=0.002), and baseline glomerular filtration rate (odds ratio=0.91; 95% confidence interval, 0.88 to 0.95; P<0.001).
In patients with chronic kidney disease, CyC seems to be a reliable marker for the early diagnosis and prognosis of contrast-induced acute kidney injury.
胱抑素 C(CyC)比血清肌酐(sCr)更敏感,能更快地检测肾功能的急性变化。
我们在 410 例连续接受冠状动脉和/或外周血管造影和/或血管成形术的慢性肾脏病患者中同时测量了 CyC 和 sCr。sCr 在基线和造影剂暴露后 24 和 48 小时进行评估。CyC 在基线和 24 小时进行评估。在 12 个月时评估主要不良事件(包括任何原因导致的死亡和透析)。在造影剂暴露后 48 小时,34 例患者(8.2%)发生造影剂诱导的急性肾损伤(定义为 sCr 增加≥0.3mg/dL)。在 87 例患者(21.2%)中检测到造影剂暴露后 24 小时 CyC 浓度增加≥10%。这是早期识别造影剂诱导的急性肾损伤高危患者的最佳 CyC 截止值(阴性预测值=100%;阳性预测值=39.1%)。根据定义的截止值(即 CyC 增加≥10%和 sCr≥0.3mg/dL),297 例患者中 16 例(5.4%)未满足任何截止值(组 1)、49 例患者中 9 例(18.4%)仅满足 CyC 增加≥10%(组 2)和 31 例患者中 9 例(29%)同时满足两个截止值(组 3)。通过逻辑回归分析,1 年时主要不良事件的独立预测因子为组 2(比值比=2.52;95%置信区间,1.17 至 5.41;P=0.02)、组 3(比值比=4.45;95%置信区间,1.72 至 11.54;P=0.002)和基线肾小球滤过率(比值比=0.91;95%置信区间,0.88 至 0.95;P<0.001)。
在慢性肾脏病患者中,CyC 似乎是造影剂诱导的急性肾损伤早期诊断和预后的可靠标志物。